Subcutaneous low-dose alemtuzumab (10 mg t.i.w. for 18 weeks) induced a 50% response rate, including 25% complete response, in 16 patients with refractory chronic lymphocytic leukemia (CLL) patients. The responses were substantial even in patients with unfavorable cytogenetics, fludarabine/rituximab refractoriness, Rai stage IV, previous infections, and age over 65 years. Subcutaneous low-dose alemtuzumab is effective in poor prognosis B-CLL, and has a particularly favourable toxicity profile.
A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia / A. Cortelezzi, M.C. Pasquini, B. Sarina, G. Bertani, F. Grifoni, M. Colombi, G. Lambertenghi Deliliers. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 90:3(2005), pp. 410-412.
A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia
A. CortelezziPrimo
;M.C. PasquiniSecondo
;F. Grifoni;G. Lambertenghi DeliliersUltimo
2005
Abstract
Subcutaneous low-dose alemtuzumab (10 mg t.i.w. for 18 weeks) induced a 50% response rate, including 25% complete response, in 16 patients with refractory chronic lymphocytic leukemia (CLL) patients. The responses were substantial even in patients with unfavorable cytogenetics, fludarabine/rituximab refractoriness, Rai stage IV, previous infections, and age over 65 years. Subcutaneous low-dose alemtuzumab is effective in poor prognosis B-CLL, and has a particularly favourable toxicity profile.
| File | Dimensione | Formato | |
|---|---|---|---|
|
410.full.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
170.38 kB
Formato
Adobe PDF
|
170.38 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
